Flora Peyvandi Introduces Breakthrough Protease-Resistant ADAMTS13 Enhancing VWF Regulation in Thrombotic Disorders
A new study published in Blood Advances by Prof. Flora Peyvandi and colleagues presents a study about a bioengineered, protease-resistant form of ADAMTS13, designed to enhance resistance to proteolytic degradation without compromising its functional regulation of von Willebrand factor (VWF)-posted on X:
“Mortality, diagnosis, and etiology of disseminated intravascular coagulation – A systematic review and meta-analysis: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation.”
Recombinant ADAMTS13 has shown therapeutic potential in thrombotic disorders such as heritable TTP and is under investigation for use in acquired TTP and sickle cell disease. However, its susceptibility to degradation by proteases like plasmin limits its efficacy, especially under thrombo-inflammatory conditions. This study introduces protease-resistant ADAMTS13 variants—specifically modified in linker regions—that retain full VWF-cleaving function under flow. These stabilized forms resist cleavage by thrombin, FXIa, kallikrein, and neutrophil-derived enzymes, without compromising antithrombotic activity. The findings suggest that protease-resistant ADAMTS13 may enhance therapeutic durability in TTP and broaden its use in thrombosis-related diseases such as ischemic stroke and myocardial infarction.
Title: Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation
Autors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Similar exciting news can be found in Hemostasis Today.
-
Sep 7, 2025, 16:14Paddy Barret on Thin Cap Fibroatheroma's Outcomes
-
Sep 6, 2025, 14:04Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
-
Sep 6, 2025, 13:48The Body Explained on Blood Clotting Pathways
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 5, 2025, 10:59New Study Featured by Rare Disease Advisor Reveals Quality-of-Life Challenges in Hemophilia
-
Sep 6, 2025, 16:43Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
-
Sep 6, 2025, 15:06Managing Gynecologic Bleeding in Anticoagulated Patients: Toolkit Co-Authored by Divyaswathi Citla Sridhar
-
Sep 6, 2025, 14:30Mattia Galli on Whether Reduction in MACE Really Depicts Situation in Spontaneous MI or Death post-PCI
-
Sep 6, 2025, 13:55Patrick Cieran Gallogly and Colleagues on Atypical Symptoms in TIA and Minor Stroke
-
Sep 6, 2025, 13:37Unfractionated Heparin Dosing in ECMO: A Systematic Review and Meta-Analysis
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 7, 2025, 16:01Congratulations to Bart Loeys on Receiving Doctor Honoris Causa!
-
Sep 6, 2025, 14:09Erin VanDyke: Shifting Attention Upstream in VTE Care Through NBCA Centers of Excellence
-
Sep 6, 2025, 12:02Caitlin Raymond on Kairos in Medicine: How Curiosity Sustains Physicians and Prevents Burnout
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 10:58Côme Bommier Recommends CRTH for Clinical Trial Training and Career Growth in Hematology